Our Executive Team

A. Smith
Mr. Smith has 19 years of sales and management experience with major pharmaceutical and the biotech companies. Mr. Smith was instrumental in establishing divisions responsible for national accounts, state and government affairs, community marketing, Department of Corrections and Department of Defence sales teams. He has launched 12 NCE's and 20 Line extensions in Orphan, Accelerated Approval and "blockbuster" categories. Prior to entering the pharmaceutical industry, Mr. Smith was controller at Swissco, Inc., a privately held printing company.

B. Ernsberger
Mr. Ernsberger has over 37 years of experience in pharmaceuticals and drug merchandising. He started his career with Whitehall-Robins Healthcare [American Home Products/Wyeth] where he established the Trade Development division and ran Wyeth Corporation's $3.5 billion OTC division. He also held management positions with Bristol-Myers, Warren-Teed and was Head of Merchandising for Eckerd Drugs. Mr. Ernsberger has received the General Merchandise Distributors Council (GMDC) Lifetime Achievement Award.

C. Keeling
Mr. Keeling has 19 years of sales/marketing and management experience including 16 years in bio-tech/pharma and wound care center management. After starting his career at AstraZeneca, he was recruited to Gilead Sciences as one of their original sales representatives in 1996. Mr. Keeling lead a team of 10 HIV sales specialists as a Region Director at Gilead and his team launched several HIV drugs, some of which remain the most successful launches in HIV therapeutics history. He left Gilead in 2008 to except a Region Director position with The Center for Wound Healing, Inc. He develops and manages hospital-based wound care centers that provide traditional wound care and hyperbaric ("HBOt") treatments to outpatients on an outsourced basis.

S. Wihler Smith
Ms. Wihler Smith has 14 years of sales/management and managed healthcare experience in the bio-tech/medical industries. She has been instrumental in establishing and expanding various markets throughout this arena. In addition, Ms. Wihler Smith has an extensive background working with managed markets and government agencies, where she was responsible for major PBM’s, CMS and Managed Care organizations. Prior to entering the pharmaceutical space she worked for a multinational financial institution in Zurich, Switzerland.

Advisory Board

T. Quintero
Mr. Quintero has 21 years of sales and management experience with roles of increasing responsibility in the sales, management, marketing and training for over 11 launches and 5 product line extensions in Orphan, Accelerated Approval and "blockbuster" products. He has lead the launch team for registration, licensing and marketing of several products in the Caribbean and Latin America.

S. Burstin, MD, PhD, FACP
Dr. Burstin obtained his MD and PhD degrees at NYU in 1975. His residency in internal medicine was at Montifiore Hospital, Albert Einstein School of Medicine in New York followed by a fellowship in Infectious Diseases at Brigham Hospital, Harvard Medical School, Boston, MA. His research includes the physiology of reovirus infection and immune response. Dr. Burstin has been chief of division of infectious diseases at the Brockton, MA VA Hospital.

J. Jimenez, MD
Dr. Jimenez has 24 years of progressive clinical, sales, marketing and management experience. Dr. Jimenez served as President and CEO of Biovet Products, Inc. where he managed overall manufacturing, marketing and sales of Equigam.

T. McCormick
Mr. McCormick has 28 years of health care experience. Early in his career, held various Sales, Marketing and Managed Care positions with increasing responsibility with Glaxo, Biogen and Pfizer. Intrigued by pharmacogenomics, he joined Quest Diagnostics to manage the Infectious Disease portfolio. He was recruited by Laboratory Corporation of America as Director of Marketing for Internal Medicine related diagnostic services. He is currently a consultant at Management Science Associates, Inc. Where he leads the efforts in strategic planning efforts for IVD, Clinical Lab and Pharmaceutical organizations. He has launched over 10 NCE's and 25 Line extensions in Orphan, Accelerated Approval and "blockbuster" categories and over 30 molecular, genomic and pharmacogenomic assays.